AbbVie closes $10.9 billion acquisition of Apogee Therapeutics, reaffirms 2026 guidance

AbbVie announced on September 3, 2026 that it had completed its acquisition of Apogee Therapeutics, Inc.¹ Under the deal terms, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.¹ Apogee's common stock ceased trading on the NASDAQ stock exchange prior to market open on Sept. 3, 2026.¹

The centerpiece of the acquisition is zumilokibart, described as a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis.¹ In a Phase 2 trial, the company reported that approximately two-thirds of patients on treatment achieved significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control.¹ Longer-term data from the same trial also support maintenance regimens of either quarterly or twice a year dosing.¹

The pipeline also includes APG273, which combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin (TSLP), a signaling protein that acts as an early trigger of inflammation in the lungs.¹ Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing.¹

On financial terms, AbbVie said the acquisition of Apogee will negatively impact adjusted diluted earnings per share by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032.¹ The company reaffirmed its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 to $14.07,¹ and reaffirmed its previously issued 2026 third-quarter adjusted diluted EPS guidance range of $3.84 to $3.88.¹